NURECABSENureca LtdHighNeutral
Announced Fri, 29 May · 20:53 IST

Nureca Limited has informed the exchange regarding the re-appointment of Mr. Saurabh Goyal as Managing Director of the company for a period of three years with effect from September 03, 2026.

Cfo ResignedKmp ResignedPromoter Family Board EntryManagement Changes View source PDF

NURECA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-15.3%1-day move
₹281.25
prior close
₹232.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.5+2.5+4.6+4.5-15.3-16.4-16.8-15.9-18.2-18.9-15.4-16.3
Up moveDown movePending
AI summary

Nureca Limited's Board meeting on May 29, 2026 approved multiple items including audited FY 2025-26 financial results showing revenue of Rs 1,472.10 million (up 28% YoY) with net profit of Rs 2.97 million. The Q4 quarter however reported a loss of Rs 61.52 million due to Rs 83.37 million fair value loss on investments. Key leadership changes include CFO Mr. Naresh Gupta resigning (effective June 26, 2026) with Mr. Chander Kant promoted internally as new CFO from June 27, 2026. The board approved re-appointment of Mr. Saurabh Goyal as Managing Director and Mr. Aryan Goyal as Whole-time Director & CEO, both for 3-year terms. Ms. Smita Goyal (sister-in-law of Aryan Goyal and spouse of Saurabh Goyal) was appointed as Additional Director (Whole Time Director) subject to shareholder approval. The board also approved Rs 100 crore capex for manufacturing medical devices and additional land purchase at Derabassi, Punjab.

Likely market impact

Shareholders should note the CFO transition amid mixed financial performance with weak Q4 results offset by full-year improvement. The appointment of a family member to the board may raise governance concerns as three Goyal family members will now hold key leadership positions.